Novo-Nordisk AS (NVO) ADR Each Repr 1 Cls B

Sell:$88.08Buy:$88.10$4.34 (5.18%)

Prices delayed by at least 15 minutes
Sell:$88.08
Buy:$88.10
Change:$4.34 (5.18%)
Deal now
Prices delayed by at least 15 minutes
Sell:$88.08
Buy:$88.10
Change:$4.34 (5.18%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Key people

Lars Fruergaard Joergensen
President, Chief Executive Officer
Henrik Poulsen
Vice Chairman of the Board
Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Maziar Mike Doustdar
Executive Vice President - International Operations
Marcus Schindler
Executive Vice President - Research and Early Development, Chief Scientific Officer
Ludovic Helfgott
Executive Vice President - Rare Disease
Martin Holst Lange
Executive Vice President - Development
David Moore
Executive Vice President - US Operations and Business Development
Tania Sabroe
Executive Vice President - Global People and Organisation
Camilla Sylvest
Executive Vice President - Commercial Strategy and Corporate Affairs
Helge Lund
Independent Chairman of the Board
Mette Boejer Jensen
Director, Employee Representative
Elisabeth Dahl Christensen
Director, Employee Representative
Liselotte Hyveled
Director, Employee Representative
Kasim Kutay
Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Denmark
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6701002056
  • Market cap
    $283.72bn
  • Employees
    76,302
  • Shares in issue
    3.39bn
  • Exchange
    Copenhagen Stock Exchange
  • Index
    Denmark-OMX-Copenhagen-All-Share-Index, TR Equity Denmark Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.